New drug plus hormone therapy for advanced breast cancer after CDK4/6 inhibitor
Part of Cancer, Skin clinical trials.
This study tests a new drug combo (sacituzumab govitecan plus hormone therapy) for people whose HR+/HER2- breast cancer has progressed after a CDK4/6 inhibitor. It aims to see if this treatment can work better than hormones alone, and it may be an option if you've not yet had chemo for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to give written consent.
- You are physically active (able to do light work or be up and about) – doctors call this ECOG 0 or 1.
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative – these are types of cancer that grow in response to hormones and lack certain protein markers.
- Your cancer must have spread or be inoperable, and it must have gotten worse while on your first CDK4/6 inhibitor treatment combined with hormone therapy, and that treatment kept working for at least 6 months.
- You have not had chemotherapy for advanced or metastatic breast cancer. If you had chemo earlier for early-stage disease, it must have been more than 12 months before your cancer returned.
- You do not have untreated brain metastases, active serious infections, or significant heart, lung, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
Hear when a new Stage IV (Metastatic) Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.